Update 2026: AI and peptide cancer research come together
In July 2026 a review article on artificial intelligence in the design of peptide cancer vaccines appeared in Frontiers in Genetics. The core point: algorithms such as NetMHCpan and newer transformer models can predict thousands of neoantigens from a tumour's DNA. That is exactly the step that could not be done by hand.
The honest figure from that same article: of all candidates the computer selects, only about 6 percent ultimately prove to be immunogenic. Predicting binding to HLA molecules now works well. Predicting whether the immune system really responds does not, by a long way. In glioblastoma the combination with checkpoint inhibitors looks most promising.
How these design models work technically is described in detail in our article on AI and the future of peptide design. Source: Frontiers in Genetics, mini-review, 29 juli 2026. All peptides at Peplife are Research Use Only and intended solely for laboratory research.
In brief · RUO
- In oncology, peptides mostly play the role of an "address label": they bind specifically to tumor cells and deliver a drug, toxin or radioactive particle there — with less damage to healthy tissue.
- There are four major research lines: peptide-drug conjugates, tumor-targeting/cell-penetrating peptides, peptide vaccines and radioligands.
- Some are already approved drugs (e.g., the radioligands Pluvicto and Lutathera).
- This is an educational overview of published research — none of the compounds here is a Peplife catalog item, and nothing here is medical advice.
What is this about?
Chemotherapy often acts like "carpet bombing": it hits cancer cells but also healthy ones. Much of modern cancer research seeks ways to aim drugs precisely at the tumor. Peptides are ideal for this: short protein chains that can bind very selectively to particular targets on tumor cells. They act as an address label that sends a "package" — a drug, a toxin, or a radioactive particle — to the right cell.
Under the hood: why peptides fit so well
Cancer cells often carry more of certain proteins (receptors) on their surface than healthy cells. A peptide can be designed to fit precisely onto such a receptor — like a key to a lock found mainly on tumours. That makes peptides attractive for three reasons: they are small (they penetrate tissue more deeply than large antibodies), selective (they bind selectively) and modular (you can attach a payload to it). This gives rise to the four research lines below.
What is a "targeting" peptide? A peptide designed to recognize and bind a protein found mainly on cancer cells, acting as a homing head that guides the payload to the tumor.
1. Peptide-drug conjugates (PDCs)
A PDC links three parts: a targeting peptide (the address label), a linker (the connection) and a drug (the payload). The peptide finds the tumor, the linker releases the drug there. 2025 reviews describe the fast-growing PDC field as a refinement of the better-known "antibody-drug conjugates," with the advantage that peptides are smaller and penetrate tissue more deeply (PMC 2025; PubMed 2025).
Study type: reviews of preclinical + clinical work.
2. Tumor-targeting & cell-penetrating peptides
Beyond delivering payloads, peptides are also studied to get into the cell (cell-penetrating peptides) or to specifically recognize tumor vessels or proteins. A 2025 review summarizes the many tumor-targeting peptides (Oncology Research / PMC), and another discusses cell-penetrating peptides as a tool in immunotherapy (Scientific Reports 2025).
3. Peptide vaccines & neoantigens
A very different approach uses peptides to train the immune system . "Neoantigen" vaccines contain protein fragments (peptides) unique to a patient's tumor, so the immune system learns to recognize them. In a phase II study (iNATURE, 2025) such a personalized peptide vaccine was combined with radiotherapy (Frontiers in Immunology).
What is a neoantigen? A small, abnormal protein fragment that occurs only on a specific patient's cancer cells (due to mutations). Because it is "new" to the body, the immune system can learn to see it as hostile.
4. Radioligands: peptides with a radioactive tail
The most clinically proven application is radioligands (PRRT — peptide receptor radionuclide therapy). Here a targeting peptide carries a radioactive atom to the tumor, irradiating the cell from within. Two are already FDA-approved: Pluvicto (¹⁷⁷Lu-PSMA-617) for certain prostate cancer — expanded to earlier use in 2025 (Novartis) — and Lutathera (¹⁷⁷Lu-DOTATATE) for neuroendocrine tumors, also for children in 2024 (FDA).
Study type: approved drugs (clinical). Illustrating the principle — not a catalog item.
Overview: four ways peptides are used
| Approach | How it works | Example | Status |
|---|---|---|---|
| Peptide-drug conjugate | address label + linker + drug | (various in development) | preclinical + clinical (2025 reviews) |
| Tumor-targeting / cell-penetrating | recognizes/enters tumor cell | targeting and CPP peptides | preclinical (2025 reviews) |
| Peptide vaccine / neoantigen | trains the immune system | iNATURE vaccine + radiotherapy | phase II study (2025) |
| Radioligand (PRRT) | peptide + radioactive atom | Pluvicto, Lutathera | FDA-approved |
Nuance & limitations
- Educational, not sales. None of the agents named is a Peplife product; they are approved drugs or research substances.
- Peptides are a tool, not a "miracle cure". They reach clinical value as a smart delivery system, not as a standalone cure.
- Long, strict path. From lab to approved drug takes years of rigorous trials — exactly why research (RUO) and clinical use remain strictly separate.
Related on Peplife · RUO
- Knowledge base: What are peptides? and FDA & peptides: what is really happening (internal pillars on the basics and regulation).
- Note: the compounds named in this article are approved drugs or research substances, not Peplife catalog items.
Frequently asked questions
Do peptides cure cancer?
No — peptides are studied and used as a delivery system or to train the immune system. Some applications are approved drugs; most are research.
What is a peptide-drug conjugate?
A targeting peptide linked to a drug, delivering the payload specifically to the tumor.
What are radioligands?
Peptides carrying a radioactive atom that irradiate the tumor from within (e.g., Pluvicto, Lutathera).
Does Peplife sell these compounds?
No. This is an educational overview; these are not catalog items.
Disclaimer
This article discusses scientific research and approved drugs and is informational only. It is not medical advice. The compounds mentioned are not Peplife products. Peplife supplies only Research Use Only (RUO)materials for laboratory research.